Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Sign In to gain access to subscriptions and/or personal tools.
Journal of Biomolecular Screening
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Web of Science (7)
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Mellor, G. W.
Right arrow Articles by Houston, J. G.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Mellor, G. W.
Right arrow Articles by Houston, J. G.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Searching for Chemokine Receptor Binding Antagonists by High Throughput Screening

Geoffrey W. Mellor

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Simon J. Fogarty

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

M. Shane O'Brien

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Miles Congreve

Exploratory Chemistry Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Martyn N. Banks

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Kirsten M. Mills

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Barbara Jefferies

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

John G. Houston

Lead Discovery Unit, Glaxo Wellcome Research and Development (GW R&D), Gunnels Wood Road, Stevenage, Hertfordshire, SG1 2NY, UK

Identification of putative drug candidates by high throughput screening is assuming enormous importance within the pharmaceutical industry, driven by increasing numbers of valid therapeutic targets from both classical and molecular biological sources. Screening is an applied discipline that requires equipment and, more importantly, thinking that is fundamentally different from more traditional, lower throughput assay methodology. This article describes the process as applied to the discovery of selective antagonists of three chemokine receptor binding systems, from the original biological targets to chemically prosecutable lead compounds, which are currently being investigated using traditional medicinal and combinatorial chemistry methods.

Journal of Biomolecular Screening, Vol. 2, No. 3, 153-157 (1997)
DOI: 10.1177/108705719700200305
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
 J Biomol ScreenHome page
M. Beggs, H. Blok, and J. Mertens
Stacker Modules Used in a High-Capacity Robotics System for High Throughput Screening Compound Replication
J Biomol Screen, December 1, 1999; 4(6): 373 - 379.
[Abstract] [PDF]